BLRX

BioLineRX

3.39 USD
+0.21
6.60%
At close Mar 19, 4:00 PM EDT
1 day
6.60%
5 days
9.35%
1 month
-12.18%
3 months
-58.04%
6 months
-86.98%
Year to date
-66.83%
1 year
-92.82%
5 years
-92.69%
10 years
-99.72%
 

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 79

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,500% more call options, than puts

Call options by funds: $16K | Put options by funds: $1K

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

0.06% less ownership

Funds ownership: 0.21% [Q3] → 0.15% (-0.06%) [Q4]

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

3% less funds holding

Funds holding: 32 [Q3] → 31 (-1) [Q4]

67% less capital invested

Capital invested by funds: $1.34M [Q3] → $439K (-$904K) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for BLRX.

Financial journalist opinion

Neutral
PRNewsWire
1 month ago
BioLineRx Issues Letter to Shareholders
- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.
BioLineRx Issues Letter to Shareholders
Neutral
PRNewsWire
2 months ago
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS.
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
Neutral
Benzinga
2 months ago
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
Neutral
PRNewsWire
2 months ago
BioLineRx Announces $10 Million Registered Direct Offering
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering.
BioLineRx Announces $10 Million Registered Direct Offering
Neutral
Seeking Alpha
3 months ago
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright Justin Walsh - Jones Trading John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
3 months ago
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC - - Entered into agreement to reduce and restructure long-term debt by ~$16.5 million - - Annual operational expenses expected to decline by over 70% following out-license of APHEXDA ® (motixafortide) commercial program to Ayrmid - - Company to continue to support motixafortide PDAC program while evaluating additional assets for development in rare diseases and oncology - - Management to host conference call today, November 25, at 8:30 am EDT - TEL AVIV, Israel , Nov. 25, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
Neutral
PRNewsWire
3 months ago
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –  – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Trans actions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET – TEL AVIV, Israel , Nov. 21, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Neutral
PRNewsWire
3 months ago
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Neutral
PRNewsWire
4 months ago
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle -  - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Neutral
PRNewsWire
5 months ago
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
– Allowance strengthens company's intellectual property estate and extends motixafortide patent protection in the U.S. through December 2041 – TEL AVIV, Israel , Oct. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040).
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Charts implemented using Lightweight Charts™